[{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Varnimcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Taiba Healthcare","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"}]

Find Clinical Drug Pipeline Developments & Deals by Taiba Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the agreement, Taiba will be responsible for the distribution and commercialization of Xolremdi (mavorixafor), an oral, once-daily treatment for WHIM syndrome in MENA region.

                          Product Name : Xolremdi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 19, 2025

                          Lead Product(s) : Mavorixafor

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Recipient : X4 Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The intended to advance CAR T-cell research development of Phase 2 trial for CD19 CAR-T IMN-003A (varnimcabtagene autoleucel) targeting B-cell malignancies, including leukemia and lymphoma.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 30, 2024

                          Lead Product(s) : Varnimcabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Immuneel Therapeutics

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 10, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Recipient : Aspargo Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory.

                          Product Name : Arikayce

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          June 14, 2021

                          Lead Product(s) : Amikacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Insmed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The distribution agreement is focused on both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.

                          Product Name : Onpattro

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          August 07, 2020

                          Lead Product(s) : Patisiran

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Alnylam Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North...

                          Product Name : Apealea

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          May 10, 2020

                          Lead Product(s) : Paclitaxel,Carboplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Elevar Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank